A multicenter, open label, first-in-human study of an oncolytic viral vector expressing an agonistic anti-CD40 antibody (NG-350A) in patients with epithelial tumors (FORTITUDE).

Aung Naing,Ecaterina Ileana Dumbrava,Ravi Murthy,Funda Meric-Bernstam,Andrew Fox,David Krige,Jo Carter,Brian Robert Champion,Paul Cockle,Barbara Koetz,Hilary McElwaine-Johnn

A multicenter, open label, first-in-human study of an oncolytic viral vector expressing an agonistic anti-CD40 antibody (NG-350A) in patients with epithelial tumors (FORTITUDE).

2019

Aung Naing
Ecaterina Ileana Dumbrava
Ravi Murthy
Funda Meric-Bernstam
Andrew Fox
David Krige
Jo Carter
Brian Robert Champion
Paul Cockle
Barbara Koetz
Hilary McElwaine-Johnn

TPS2668Background: NG-350A is a transgene modified variant of the oncolytic platform virus enadenotucirev (EnAd) which expresses a fully human agonist anti-cluster of differentiation 40 (anti-CD40)...

Keywords:

Oncolytic virus
CD40
Agonistic behaviour
Human study
Antibody
Viral vector
Pathology
Cancer research
Medicine
Virus
Transgene
open label
Agonist
Enadenotucirev

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations